Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben G L Vanneste, Ryan Davey, Rebecca Montgomery, Jeremy Ruben, Farshad Foroudi, Braden Higgs, Charles Lin, Avi Raman, Nicholas Hardcastle, Michael S Hofman, Richard De Abreu Lourenco, Mark Shaw, Pascal Mancuso, Daniel Moon, Lih-Ming Wong, Nathan Lawrentschuk, Simon Wood, Nicholas R Brook, Tomas Kron, Jarad Martin, David Pryor
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. METHODS: This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands. Eligible patients aged 18 years or older had biopsy-confirmed diagnosis of primary renal cell cancer, with only a single lesion; were medically inoperable, were at high risk of complications from surgery, or declined surgery; and had an Eastern Cooperative Oncology Group performance status of 0-2...
March 2024: Lancet Oncology